

Perspective

Open Access



Lactobacillus, glycans and drivers of health in the vaginal microbiome

Rosemary Sanozky-Dawes, Rodolphe Barrangou

Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, NC 27606, USA.

Correspondence to: Prof. Rodolphe Barrangou, Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, 840 Main Campus Drive, Raleigh, NC 27606, USA. E-mail: rbarran@ncsu.edu

How to cite this article: Sanozky-Dawes R, Barrangou R. *Lactobacillus*, glycans and drivers of health in the vaginal microbiome. *Microbiome Res Rep* 2022;1:18. <https://dx.doi.org/10.20517/mrr.2022.03>

Received: 9 Feb 2022 **First Decision:** 18 Mar 2022 **Revised:** 8 Apr 2022 **Accepted:** 29 Apr 2022 **Published:** 13 May 2022

Academic Editor: Marco Ventura **Copy Editor:** Peng-Juan Wen **Production Editor:** Peng-Juan Wen

Abstract

A microbiome consists of microbes and their genomes, encompassing bacteria, viruses, fungi, protozoa, archaea, and eukaryotes. These elements interact dynamically in the specific environment in which they reside and evolve. In the past decade, studies of various microbiomes have been prevalent in the scientific literature, accounting for the shift from culture-dependent to culture-independent identification of microbes using new high-throughput sequencing technologies that decipher their composition and sometimes provide insights into their functions. Despite tremendous advances in understanding the gut microbiome, relatively little attention has been devoted to the vaginal environment, notably regarding the ubiquity and diversity of glycans which denote the significant role they play in the maintenance of homeostasis. Hopefully, emerging technologies will aid in the determination of what is a healthy vaginal microbiome, and provide insights into the roles of *Lactobacillus*, glycans and microbiome-related drivers of health and disease.

Keywords: Glycans, vaginal, microbiome, *Lactobacillus*, immunity

THE VAGINAL MICROBIOME

The human vaginal microbiome comprises a diverse set of organisms that can associate with health or disease and vary across populations^[1-3]. It is a complex ecosystem, varying over the course of a woman's life, constantly fluctuating during the menstrual cycle^[4]. Historically, five community state types (CSTs) have



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



been used to describe the vaginal microbiome, encompassing four *Lactobacillus*-dominant communities that primarily consist of *L. crispatus*, *L. gasseri*, *L. jensenii*, and *L. iners*, and one non-*Lactobacillus* dominant diverse community^[5]. Altogether, the *Lactobacillus*-dominated groups occur in approximately 70% of women^[6]. The non-*Lactobacillus* dominant CST typically comprises *Gardnerella*, *Prevotella*, *Sneathia*, *Atopobium*, *Molibuncus*, *Clostridium*, *Corynebacterium*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, and *Mycoplasma*^[3,7-10]. Although a diversity of gut microbes is typically associated with health, it is not the case in vaginal microbiomes. Indeed, most vaginal microbial populations are dominated by a single genus, *Lactobacillus*, characterized by Gram-positive anaerobic or microaerophilic rods with peptidoglycan cell walls^[11]. This genus is commonly associated with better clinical outcomes^[12]. Although diverse *Lactobacillus* species are associated with a healthy vaginal microbiome, they all usually produce D- and L-lactic acid, which is inhibitory to pathogens and creates anti-inflammatory conditions^[13-15]. However, some species like *L. iners* produce moderate amounts of L-lactic acid, but do not produce the D-isomer^[14-16]. Besides their biochemical attributes, structural elements on the bacterial surface also contribute to the microbe-host molecular dialogue^[17]. Indeed, microbial recognition hinges on the presentation of cell surface components, especially glycans that interact with host epithelial and immune cells^[17-20]. The surface composition differs across species such as *L. gasseri*, *L. jensenii*, *L. iners* and *L. crispatus*, and others, notably with regard to S-layers. Of note, *L. crispatus* is the only characterized vaginal *Lactobacillus* that produces an S-layer, which is comprised of non-covalently bound “crystalline arrays of self-assembling proteins found outermost on the cell wall”^[11].

SURFACE COMPONENTS

The S-layer and S-layer-associated proteins (SLAPs) of *Lactobacillus acidophilus* have been studied and characterized most extensively amongst lactobacilli^[11,21]. Such S-layers are associated with cell shape, enhanced adherence to host epithelial cells, and immunomodulatory responses^[11,22]. Dendritic cells (DCs) are involved in molecular pattern recognition through sensors like toll-like receptors (TLRs). Studies involving S-layer proteins of the widely commercialized probiotic strain *L. acidophilus* NCFM^[23] have implicated SlpA, SlpB, and SlpX in immunomodulation. In particular, SlpA has been shown to interact with receptors on antigen-presenting DCs, which are important sentinels for mucosal surfaces^[24]. Likewise, the interaction between NCFM and DC-SIGN (Dendritic Cell-Specific ICAM-3 intercellular adhesion molecule grabbing non-integrin)^[17] receptor drives the production of anti-inflammatory IL-10, whereas the interaction of an NCFM mutant with a chromosomal inversion over-expressing *slpB* and under-expressing *slpA* led to the production of proinflammatory cytokines^[24]. The homeostatic anti-inflammatory properties of SlpA were shown to mitigate murine colitis^[25] and also act via DCs to trigger signaling pathways that inhibit viral infections^[26].

The S-layer of *L. acidophilus* provides a scaffold for numerous SLAPs that are secreted, non-covalently bound^[21], and display important surface features^[11,27]. Hymes *et al.*^[28] characterized a SLAP binding to fibronectin, and Johnson and Klaenhammer^[29] described another SLAP, the AcmB autolysin, which is involved with *in vitro* binding to mucin and the extracellular matrix proteins fibronectin, collagen, and laminin. The extracellular matrix is a network of molecules produced by resident cells, providing structural support for cells and tissues^[30] and regulating cell signaling and adhesion^[31]. There are also reports exploring the S-layer and S-layer associated proteins of *Lactobacillus crispatus*. Antikainen *et al.*^[32-34] demonstrated that S-layer proteins of *L. crispatus* adhere to collagen, and laminin in the context of intestinal cells. An S-layer producing vaginal *L. crispatus* isolate was highly adherent to cervicovaginal epithelial cells and was antagonistic to pathogens of the genitourinary tract^[35,36]. *In silico* analyses showed the presence of AcmB orthologs in other S-layer-producing *Lactobacillus*^[29]. When comparing *L. crispatus* genomes, Pan *et al.*^[37] found heterogeneity regarding the presence of autolysin and *acmB*-type genes in isolates, though no clear

association with a particular isolation source was observed. Furthermore, Tytgat and Lebeer^[38] highlight that bacterial glycoconjugates at the microbial surface, including S-layers, may be glycosylated. In fact, microbial glycans comprise much of the bacterial cell surface^[39]. To date, S-layer glycans have only been confirmed in *L. buchneri* and *L. kefir*^[40]. Thus, future studies should determine whether *L. acidophilus* and other *Lactobacillus* S-layer proteins are glycosylated^[41].

GLYCOSYLATION AND THE GLYCOME

The glycome is the entirety of a cell's carbohydrates, either free or as moieties of glycoconjugated macromolecules. Almost all cells are surrounded by glycans, forming a "sugar jacket" comprising proteoglycans, glycosphingolipids, and glycoproteins that form a glycocalyx^[42]. In vertebrates, mucosal glycan chains typically terminate in various sialic acid molecules^[43,44]. Within the glycome, the negatively charged sialome^[45] plays a role in signaling by concealing antigens on cell surfaces, which consequently appear as "self", thereby weakening immunoreactivity^[46]. The diverse functions of glycans include structural modularity with various glycoconjugates, and providing specificity for glycan-binding proteins and receptors^[30,42,47]. Both receptors and ligands may contain essential glycan domains, such as pattern-recognition receptors, encompassing TLRs which are transmembrane glycoproteins that have evolved to recognize conserved molecular patterns on microbial surfaces, typically referred to as MAMPs (Microorganism-Associated Microbial Patterns) that may also contain glycans^[17,18,48]. Glycosylation is an essential regulatory mechanism for post-translational processing, which plays a crucial role in the assignment of protein structure, function, and stability, especially 3-D conformation. This in turn influences protein-protein interactions like signaling^[42] as well as eukaryotic viral and bacteriophage attachment^[49]. Some Interleukins, cytokines, viral coat proteins, and G protein-coupled receptors are glycosylated, as well as immunoglobulins and hormones such as gonadotropins, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone^[50-52]. "Essentially all surface-localized immune receptors are glycoproteins"^[53]. Glycans are integral for immune system modulation and interaction with cells such as macrophages, monocytes, natural killer cells, antigen-presenting cells like dendritic cells, and T cells. These interactions impact both innate and adaptive immunities, cytokine production, and epithelial cell responses^[18,53]. Glycans can exert dual immune roles, acting either in an inhibitory or stimulatory manner^[18,19], and can be involved in tolerance or autoimmunity^[18-20].

On the host side, the vaginal mucus is also highly glycosylated. It is composed of glycoprotein mucins, other secreted proteins like immunoglobulins^[54], and antimicrobial peptides produced by mucosal epithelial cells and neutrophils, some of which bind glycans^[55,56]. The branched carbohydrate moieties can make up to 80% of mucin weight^[54] and usually terminate in an outermost sialic acid residue^[57]. Mucus sialoglycoproteins are believed to entrap microorganisms, protecting epithelial cells against infection. Cell surface mucins can bind pathogens, indicating a role of mucus in the innate immunity of the female genital tract^[12,57,58]. Consequently, the glycome status of host cells, commensal microbes, and mucosal surfaces in a microbiome are important in the maintenance of homeostasis and health, implying that glycome disruption could lead to dysbiosis.

BACTERIAL VAGINOSIS

In the context of women's health, bacterial vaginosis (BV) is a prevalent form of vaginal dysbiosis associated with a variety of adverse health outcomes^[59]. It is often found in non-*Lactobacillus*-dominated microbiomes^[3,4,10]. Biofilm presence on vaginal epithelial cells is an important factor in the evolution of BV and explains episodes of recurrent infections^[60]. A signature of BV is the presence of a dense polymicrobial biofilm on the vaginal surface believed to be initiated by *Gardnerella vaginalis*, providing a scaffold for other species to adhere to^[10]. An under-reported factor in biofilm formation is glycosyltransferase activity, as well

as the destructive action of sialidases on the protective mucosal glycan surfaces of vaginal epithelia, which possibly facilitates adhesion of vaginal pathogens such as *Gardnerella* and *Prevotella*^[61,62].

Moncla *et al.*^[54] have shown that glycosidase and sialidase activity is associated with a reduced number of sialic acid binding sites, a virulence factor in pathogens of mucosal surfaces, and a feature of BV^[58]. Two bacteria typically associated with BV are *Gardnerella vaginalis* and *Prevotella bivia*. Sialidase is produced by many *P. bivia* isolates, but only by 25% of *G. vaginalis* isolates. The sialidase produced by *Prevotella* is cell-bound, whereas *Gardnerella* sialidases are extracellular and affect the vaginal environment differently^[54,58,62]. When sialidases are secreted, they may remove sialic acid residues from carbohydrate chains distant from the organism^[63], and subsequently affect the function of cells and molecules like immunoglobulins. This would make sialic acids available to other organisms capable of their catabolism and furthermore, expose the “open” carbohydrate chains to exo- and endo-glycosidase attack as well as other hydrolytic enzymes like mucinases, sulfatases, proline dipeptidases, and fucosidases^[19,58,64-66]. Contributors to *Essentials of Glycobiology*^[67], relate fascinating abilities of some pathogens to produce sialidases that “steal” sialic acids from the periphery of host cell glycans to add to their surface for use as immuno-camouflage. For example, some *Neisseria gonorrhoeae* have efficient sialidases that enable this mimicry^[44,67]. These enzymes may be responsible for altering the vaginal and cervical glycomes, “disrupting dynamic systems responding to internal signals like hormones and to other signals from members of the vaginal microbiome”^[58]. Furthermore, Moncla *et al.*^[54,58] demonstrated this disruption by evaluating the glycome of cervicovaginal lavage and cervicovaginal fluid samples from women with BV *vs.* healthy women. In both BV sample types, they report increased activity of distinct glycosidases such as sialidase, α -galactosidase, β -galactosidase, and α -glucosidase, which are associated with decreased sialic acid binding sites and mannose-binding sites^[54]. The measurement of binding sites utilized lectins, which are proteins that bind sugar moieties of molecules and are so specific that frequently isomeric glycans with identical sugar content can be distinguished^[68]. Lectins are found in humans, animals, plants, lichens, bacteria, and higher fungi, and have roles in “cell-cell interactions, signaling pathways, cell development, and immune responses”^[69]. In the review of Vagios and Mitchell^[12], an argument is presented for more research focusing on how mucins and glycans influence vaginal colonization and affect host-microbe interactions, though there is a general paucity of studies investigating the glycome^[54,58,70].

HOST-MICROBE INTERACTIONS

In their insightful opinion, Tytgat and de Vos^[17] equate the “array of glycoconjugates on bacterial surfaces as strain-specific barcodes generating diversity as ligands for shaping microbial-host interactions”^[17]. Even though the field of bacterial glycobiology is expanding, the scarcity of studies on bacterial cell surface protein glycosylation in general, and in the context of women’s health is perplexing. Sun *et al.*^[71] carried out a comparative genomic analysis of 213 lactobacilli, and highlighted the diversity of glycotransferases documented. However, surface glycoconjugates cannot be inferred genetically, since they are post-translational modifications, highlighting the need for functional and biochemical characterization^[23]. Likewise, genomic studies of *L. gasseri*^[72] and *L. jensenii*^[73] have not substantiated their beneficial roles in the vaginal microbiome. Petrova *et al.*^[6] report that *L. jensenii* can reduce adherence and invasiveness of *N. gonorrhoeae*, and that *L. gasseri* can displace the gonorrhea coccus, but these traits can vary across strains. A characteristic of some *L. crispatus* and *L. gasseri* strains is the presence of genes encoding mucin binding proteins, but additional functional and mechanistic insights are needed.^[12] The role of *L. iners* in contributing to vaginal health or disease is unclear and sometimes subject to controversy^[66]. Indeed, *L. iners* shares attributes with *Gardnerella*, a pathogen associated with BV, such as: a small genome indicative of symbiotic/parasitic lifestyle, moderate lactic acid production^[6,14,15], secretion of a cholesterol-dependent cytolyisin, and overgrowth during menstruation^[10,16]. Some believe that *L. iners* may be a transitional

organism between health and dysbiosis^[10,74]. Actually, *L. iners*, is found in low to moderate abundance in the non-*Lactobacillus*-dominated vaginal microbiome^[5,65].

A bacterial surface glycoconjugate barcode sends a molecular message to other community members^[17]. A critical step in deciphering these barcoded messages is to determine the glycosylation of surface proteins in vaginal lactobacilli of interest. This can be achieved by cell shaving with trypsin^[75] or by Lithium chloride extraction of S-layer proteins and SLAPs^[11,27] and determination of glycosylation using lectin microarrays, monoclonal antibodies, synthetic glycans, or prediction tools^[39,74,76,77]. In particular, it would be interesting to determine *L. crispatus* surface glycosylation given the association of this species with vaginal health and homeostasis^[78]. Besides, *L. crispatus* isolates from vaginal, intestinal, and poultry sources display very different S-layer and SLAP profiles, providing a unique opportunity to determine glycome diversity across environments for one species^[21].

Glycogen is a major carbohydrate source due to its cyclical release from vaginal epithelial cells. Many commensals rely on host amylases to break it down into usable sugars. Van der Veer *et al.*^[79] 2019 found some *L. crispatus* isolates with intact pullulanase type 1 genes, enabling them to directly utilize glycogen, which would provide a competitive advantage. Genomes of *L. crispatus* encode diverse hypervariable content, including prophages, autolysins, bacteriocins, and various systems related to mobile genetic elements such as plasmid stabilization systems, toxin-antitoxin systems, and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) and associated sequences CRISPR-Cas immune systems^[37,80]. Studies have reported genomic islands encoding enzymes involved in exopolysaccharide (EPS) production on plasmids in *L. crispatus*, which could enhance adherence, biofilm formation, and exclusion of pathogens^[79]. Yet, it is unclear how the immunological *L. crispatus* “message” differs between S-layer presentation and EPS, and whether *L. crispatus* alters its surface glycome via EPS. It would be illuminating to determine the glycome of all major vaginal microbiome bacteria. Since many components of extracellular matrices are glycosylated, the ECM of the vaginal microbiome should be explored^[31,81]. Importantly, the effects of other factors in play should also be determined, notably the virome^[49] mycobiome^[82], hormones^[13,58], metabolites^[7,83], stress^[14], male factor transfers^[3], sexual partners^[6], douching^[58,84], and endocrine disruptors^[85]. Unfortunately, since the human cervico-vaginal environment possesses unique attributes such as a particularly low pH, due to *Lactobacillus* lactic acid production^[6,15], there is no adequate animal model. Nevertheless, we could exploit rising technologies such as “organ-on-a-chip”^[86] or 3D EpiVaginal tissueTM^[87] for future studies.

CONCLUSIONS

Despite tremendous advances in the study of the intestinal microbiome, the relative paucity of studies on the vaginal microbiome is puzzling. A deeper and more comprehensive understanding of microbial dynamics and bacterial functions in the vaginal microbiome would drive the development of novel products to maintain, enhance or restore vaginal health and prevent or treat dysbiosis. This could also enable the development of biomarkers to detect microbiome aberrations and diagnose unhealthy conditions^[6]. Historically, our limited understanding has also been hampered by the lack of glycoscience-related tools, though recent efforts are encouraging, promoted by the Consortium of Functional Glycomics and international entities such as EuroCarb and the Japanese Consortium for Glycobiology and Glycotechnology^[53].

McKittrick *et al.*^[39] summarized topics covered at a recent NIH workshop entitled “Glycoscience and Immunology at the Crossroads of Biology.” They present a Venn diagram where immunology, microbiology, and glycobiology overlap to encompass glycoscience, infection, and immunity. Participants




Figure 1. Vaginal homeostasis vs. dysbiosis. Glycobiology is key to understanding interactions within the vaginal microbiome since many elements encompassing the microbiota and the host are glycosylated or bind glycans. The immune state is affected^[90] in different ways between a healthy state of homeostasis (A) and a disease state of symbiosis, which in turn contributes to either health (A) or dysbiosis (B) characterized by distinct commensals and pathogens interacting with host factors and cells. (A) Homeostasis. *Lactobacillus crispatus* is deemed to be the preferred vaginal microbiome commensal when dominant due to its high lactic acid production, from glycogen degradation, resulting in beneficial low pH. (B) Dysbiosis. This condition does not have the beneficial protective effects of low pH. Presented by multi-species, non-*Lactobacillus* flora, including pathogens such as *Prevotella* and *Gardnerella*. Virulence factors are produced such as: biofilms, hydrolytic enzymes (e.g., sialidases), and cytolysins which can lead to the breakdown of mucins and epithelial cells, disruption of the homeostatic glycome, and immune response (e.g., deglycosylation of immunoglobulins and activation of immune factors). These conditions in turn promote the rise of undesirable members of the microbiome, such as viruses, yeast, and even protozoa^[6,91]. Figure created using BioRender.com.

discussed the need to determine glycan structures, linkages, stereochemical orientation, and functionality^[39], as widespread essential factors with variable chain length, linkage, and branching with inherent functional differences^[88]. Given the implication of glycans in cell activation, differentiation, and development, a deeper understanding of their role in women's health would be beneficial^[42,89]. Glycome studies will complement genomic and functional analyses of the vaginal microbiome [Figure 1] and reveal the importance of glycans in other microbiomes. This will open new avenues to manipulate the composition and function of key bacterial species driving women's health and disease.

DECLARATIONS

Authors' contributions

Wrote the manuscript: Sanozky-Dawes R

Edited the manuscript: Barrangou R

Availability of data and materials

Not applicable.

Financial support and sponsorship

The authors acknowledge internal support from North Carolina State University.

Conflicts of interest

Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2022.

REFERENCES

1. Stout MJ, Wylie TN, Gula H, Miller A, Wylie KM. The microbiome of the human female reproductive tract. *Current Opinion in Physiology* 2020;13:87-93. [DOI](#)
2. Kho ZY, Lal SK. The human gut microbiome - a potential controller of wellness and disease. *Front Microbiol* 2018;9:1835. [DOI](#) [PubMed](#) [PMC](#)
3. Koedooder R, Mackens S, Budding A, et al. Identification and evaluation of the microbiome in the female and male reproductive tracts. *Hum Reprod Update* 2019;25:298-325. [DOI](#) [PubMed](#)
4. Chen X, Lu Y, Chen T, Li R. The female vaginal microbiome in health and bacterial vaginosis. *Front Cell Infect Microbiol* 2021;11:631972. [DOI](#) [PubMed](#) [PMC](#)
5. France M, Alizadeh M, Brown S, Ma B, Ravel J. Towards a deeper understanding of the vaginal microbiota. *Nat Microbiol* 2022;7:367-78. [DOI](#) [PubMed](#) [PMC](#)
6. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. *Front Physiol* 2015;6:81. [DOI](#) [PubMed](#) [PMC](#)
7. Delgado-Diaz DJ, Tyssen D, Hayward JA, Gugasyan R, Hears AC, Tachedjian G. Distinct immune responses elicited from cervicovaginal epithelial cells by lactic acid and short chain fatty acids associated with optimal and non-optimal vaginal microbiota. *Front Cell Infect Microbiol* 2019;9:446. [DOI](#) [PubMed](#) [PMC](#)
8. Kaambo E, Africa C, Chambuso R, Passmore JS. Vaginal microbiomes associated with aerobic vaginitis and bacterial vaginosis. *Front Public Health* 2018;6:78. [DOI](#) [PubMed](#) [PMC](#)
9. Vaneechoutte M. The human vaginal microbial community. *Res Microbiol* 2017;168:811-25. [DOI](#) [PubMed](#)
10. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: friend or foe? *Trends Microbiol* 2017;25:182-91. [DOI](#) [PubMed](#)
11. Johnson B, Selle K, O'Flaherty S, Goh YJ, Klaenhammer T. Identification of extracellular surface-layer associated proteins in Lactobacillus acidophilus NCFM. *Microbiology (Reading)* 2013;159:2269-82. [DOI](#) [PubMed](#) [PMC](#)
12. Vagios S, Mitchell CM. Mutual preservation: a review of interactions between cervicovaginal mucus and microbiota. *Front Cell Infect Microbiol* 2021;11:676114. [DOI](#) [PubMed](#) [PMC](#)
13. Gliniewicz K, Schneider GM, Ridenhour BJ, et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. *Front Microbiol* 2019;10:193. [DOI](#) [PubMed](#) [PMC](#)
14. Amabebe E, Anumba DOC. The vaginal microenvironment: the physiologic role of Lactobacilli. *Front Med (Lausanne)* 2018;5:181. [DOI](#) [PubMed](#) [PMC](#)
15. Witkin SS, Linhares IM. Why do Lactobacilli dominate the human vaginal microbiota? *BJOG* 2017;124:606-11. [DOI](#) [PubMed](#)
16. Vaneechoutte M. Lactobacillus iners, the unusual suspect. *Res Microbiol* 2017;168:826-36. [DOI](#) [PubMed](#)
17. Tytgat HLP, de Vos WM. Sugar coating the envelope: glycoconjugates for microbe-host crosstalk. *Trends Microbiol* 2016;24:853-61. [DOI](#) [PubMed](#)
18. Pereira MS, Alves I, Vicente M, et al. Glycans as key checkpoints of T cell activity and function. *Front Immunol* 2018;9:2754. [DOI](#) [PubMed](#) [PMC](#)
19. Clark GF, Schust DJ. Manifestations of immune tolerance in the human female reproductive tract. *Front Immunol* 2013;4:26. [DOI](#) [PubMed](#) [PMC](#)
20. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. *Nat Rev Immunol* 2009;9:338-52. [DOI](#) [PubMed](#)
21. Johnson BR, Hymes J, Sanozky-Dawes R, Henriksen ED, Barrangou R, Klaenhammer TR. Conserved S-layer-associated proteins revealed by exoproteomic survey of S-layer-forming Lactobacilli. *Appl Environ Microbiol* 2016;82:134-45. [DOI](#) [PubMed](#) [PMC](#)
22. Hymes JP, Klaenhammer TR. Stuck in the middle: fibronectin-binding proteins in gram-positive bacteria. *Front Microbiol* 2016;7:1504. [DOI](#) [PubMed](#) [PMC](#)
23. Lin B, Qing X, Liao J, Zhuo K. Role of protein glycosylation in host-pathogen interaction. *Cells* 2020;9:1022. [DOI](#) [PubMed](#) [PMC](#)
24. Konstantinov SR, Smidt H, de Vos WM, et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell

- and T cell functions. *Proc Natl Acad Sci U S A* 2008;105:19474-9. DOI PubMed PMC
25. Lightfoot YL, Selle K, Yang T, et al. SIGNR3-dependent immune regulation by *Lactobacillus acidophilus* surface layer protein A in colitis. *EMBO J* 2015;34:881-95. DOI PubMed PMC
 26. Acosta M, Geoghegan EM, Lepenies B, Ruzal S, Kielian M, Martinez MG. Surface (S) layer proteins of *Lactobacillus acidophilus* block virus infection via DC-SIGN interaction. *Front Microbiol* 2019;10:810. DOI PubMed PMC
 27. Klotz C, Goh YJ, O'Flaherty S, Barrangou R. S-layer associated proteins contribute to the adhesive and immunomodulatory properties of *Lactobacillus acidophilus* NCFM. *BMC Microbiol* 2020;20:248. DOI PubMed PMC
 28. Hymes JP, Johnson BR, Barrangou R, Klaenhammer TR. Functional analysis of an S-layer-associated fibronectin-binding protein in *Lactobacillus acidophilus* NCFM. *Appl Environ Microbiol* 2016;82:2676-85. DOI PubMed PMC
 29. Johnson BR, Klaenhammer TR. Acmb is an S-layer-associated β -N-acetylglucosaminidase and functional autolysin in *Lactobacillus acidophilus* NCFM. *Appl Environ Microbiol* 2016;82:5687-97. DOI PubMed PMC
 30. Varki A. Biological roles of glycans. *Glycobiology* 2017;27:3-49. DOI PubMed PMC
 31. Karamanos NK, Theocharis AD, Piperigkou Z, et al. A guide to the composition and functions of the extracellular matrix. *FEBS J* 2021;288:6850-912. DOI PubMed
 32. Antikainen J, Anton L, Sillanpää J, Korhonen TK. Domains in the S-layer protein CbsA of *Lactobacillus crispatus* involved in adherence to collagens, laminin and lipoteichoic acids and in self-assembly. *Mol Microbiol* 2002;46:381-94. DOI PubMed
 33. Sillanpää J, Martínez B, Antikainen J, et al. Characterization of the collagen-binding S-layer protein CbsA of *Lactobacillus crispatus*. *J Bacteriol* 2000;182:6440-50. DOI PubMed PMC
 34. Sun Z, Kong J, Hu S, Kong W, Lu W, Liu W. Characterization of a S-layer protein from *Lactobacillus crispatus* K313 and the domains responsible for binding to cell wall and adherence to collagen. *Appl Microbiol Biotechnol* 2013;97:1941-52. DOI PubMed
 35. Abramov V, Khlebnikov V, Kosarev I, et al. Probiotic properties of *Lactobacillus crispatus* 2029: homeostatic interaction with cervicovaginal epithelial cells and antagonistic activity to genitourinary pathogens. *Probiotics Antimicrob Proteins* 2014;6:165-76. DOI PubMed
 36. Abramov VM, Kosarev IV, Pripitnevich TV, et al. S-layer protein 2 of *Lactobacillus crispatus* 2029, its structural and immunomodulatory characteristics and roles in protective potential of the whole bacteria against foodborne pathogens. *Int J Biol Macromol* 2020;150:400-12. DOI PubMed
 37. Pan M, Hidalgo-Cantabrana C, Barrangou R. Host and body site-specific adaptation of *Lactobacillus crispatus* genomes. *NAR Genom Bioinform* 2020;2:lqaa001. DOI PubMed PMC
 38. Tytgat HL, Lebeer S. The sweet tooth of bacteria: common themes in bacterial glycoconjugates. *Microbiol Mol Biol Rev* 2014;78:372-417. DOI PubMed PMC
 39. McKittrick TR, Ackerman ME, Anthony RM, et al. The crossroads of glycoscience, infection, and immunology. *Front Microbiol* 2021;12:731008. DOI PubMed PMC
 40. Hynönen U, Palva A. *Lactobacillus* surface layer proteins: structure, function and applications. *Appl Microbiol Biotechnol* 2013;97:5225-43. DOI PubMed PMC
 41. Fina Martin J, Palomino MM, Cutine AM, et al. Exploring lectin-like activity of the S-layer protein of *Lactobacillus acidophilus* ATCC 4356. *Appl Microbiol Biotechnol* 2019;103:4839-57. DOI PubMed
 42. Varki A, Gagneux P. Biological functions of glycans. In: Varki A, Cummings RD, Esko JD, et al., editors. *Essentials of glycobiology* [Internet]. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 7. DOI PubMed
 43. Schauer R. Sialic acids as regulators of molecular and cellular interactions. *Curr Opin Struct Biol* 2009;19:507-14. DOI PubMed PMC
 44. Varki A. Sialic acids in human health and disease. *Trends Mol Med* 2008;14:351-60. DOI PubMed PMC
 45. Cohen M, Varki A. The sialome - far more than the sum of its parts. *OMICS* 2010;14:455-64. DOI PubMed
 46. Lübbers J, Rodríguez E, van Kooyk Y. Modulation of immune tolerance via siglec-sialic acid interactions. *Front Immunol* 2018;9:2807. DOI PubMed PMC
 47. Cummings RD, Schnaar RL, Esko JD, Drickamer K, Taylor ME. Principles of glycan recognition. In: Varki A, Cummings RD, Esko JD, et al., editors. *Essentials of glycobiology* [Internet]. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 29. DOI PubMed
 48. Mariano VS, Zorzetto-Fernandes AL, da Silva TA, et al. Recognition of TLR2 N-glycans: critical role in ArtinM immunomodulatory activity. *PLoS One* 2014;9:e98512. DOI PubMed PMC
 49. Simpson DJ, Sacher JC, Szymanski CM. Exploring the interactions between bacteriophage-encoded glycan binding proteins and carbohydrates. *Curr Opin Struct Biol* 2015;34:69-77. DOI PubMed
 50. Bousfield GR, May JV, Davis JS, Dias JA, Kumar TR. In vivo and in vitro impact of carbohydrate variation on human follicle-stimulating hormone function. *Front Endocrinol (Lausanne)* 2018;9:216. DOI PubMed PMC
 51. Campo S, Andreone L, Ambao V, Urrutia M, Calandra RS, Rulli SB. Hormonal regulation of follicle-stimulating hormone glycosylation in males. *Front Endocrinol (Lausanne)* 2019;10:17. DOI PubMed PMC
 52. Willey KP. An elusive role for glycosylation in the structure and function of reproductive hormones. *Hum Reprod Update* 1999;5:330-55. DOI PubMed
 53. Rabinovich GA, van Kooyk Y, Cobb BA. Glycobiology of immune responses. *Ann N Y Acad Sci* 2012;1253:1-15. DOI PubMed PMC

54. Moncla BJ, Chappell CA, Mahal LK, Debo BM, Meyn LA, Hillier SL. Impact of bacterial vaginosis, as assessed by Nugent criteria and hormonal status on glycosidases and lectin binding in cervicovaginal lavage samples. *PLoS One* 2015;10:e0127091. DOI PubMed PMC
55. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. *Front Cell Infect Microbiol* 2016;6:194. DOI PubMed PMC
56. Yarbrough VL, Winkle S, Herbst-Kralovetz MM. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. *Hum Reprod Update* 2015;21:353-77. DOI PubMed
57. Lewis AL, Lewis WG. Host sialoglycans and bacterial sialidases: a mucosal perspective. *Cell Microbiol* 2012;14:1174-82. DOI PubMed
58. Moncla BJ, Chappell CA, Debo BM, Meyn LA. The effects of hormones and vaginal microflora on the glycome of the female genital tract: cervical-vaginal fluid. *PLoS One* 2016;11:e0158687. DOI PubMed PMC
59. Morrill S, Gilbert NM, Lewis AL. *Gardnerella vaginalis* as a cause of bacterial vaginosis: appraisal of the evidence from in vivo models. *Front Cell Infect Microbiol* 2020;10:168. DOI PubMed PMC
60. Hardy L, Cerca N, Jaspers V, Vaneechoutte M, Crucitti T. Bacterial biofilms in the vagina. *Res Microbiol* 2017;168:865-74. DOI PubMed
61. Castro J, Machado D, Cerca N. Unveiling the role of *Gardnerella vaginalis* in polymicrobial bacterial vaginosis biofilms: the impact of other vaginal pathogens living as neighbors. *ISME J* 2019;13:1306-17. DOI PubMed PMC
62. Lewis WG, Robinson LS, Gilbert NM, Perry JC, Lewis AL. Degradation, foraging, and depletion of mucus sialoglycans by the vagina-adapted Actinobacterium *Gardnerella vaginalis*. *J Biol Chem* 2013;288:12067-79. DOI PubMed PMC
63. Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. *J Physiol* 2017;595:451-63. DOI PubMed PMC
64. Hoang T, Toler E, DeLong K, et al. The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis. *PLoS Pathog* 2020;16:e1008236. DOI PubMed PMC
65. France MT, Fu L, Rutt L, et al. Insight into the ecology of vaginal bacteria through integrative analyses of metagenomic and metatranscriptomic data. *Genome Biol* 2022;23:66. DOI PubMed PMC
66. France MT, Rutt L, Narina S, et al. Complete genome sequences of six *Lactobacillus iners* strains isolated from the human vagina. *Microbiol Resour Announc* 2020;9:e00234-20. DOI PubMed PMC
67. Varki A, Schnaar RL, Schauer R. Sialic acids and other nonulosonic acids. In: Varki A, Cummings RD, Esko JD, et al., editors. *Essentials of glycobiology* [Internet]. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 15. DOI PubMed
68. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. *Lab Invest* 2007;87:851-7. DOI PubMed PMC
69. Raposo CD, Canelas AB, Barros MT. Human lectins, their carbohydrate affinities and where to find them. *Biomolecules* 2021;11:188. DOI PubMed PMC
70. Koppolu S, Wang L, Mathur A, et al. Vaginal product formulation alters the innate antiviral activity and glycome of cervicovaginal fluids with implications for viral susceptibility. *ACS Infect Dis* 2018;4:1613-22. DOI PubMed
71. Sun Z, Harris HM, McCann A, et al. Expanding the biotechnology potential of lactobacilli through comparative genomics of 213 strains and associated genera. *Nat Commun* 2015;6:8322. DOI PubMed PMC
72. Zhou X, Yang B, Stanton C, et al. Comparative analysis of *Lactobacillus gasseri* from Chinese subjects reveals a new species-level taxa. *BMC Genomics* 2020;21:119. DOI PubMed PMC
73. Lee S, You HJ, Kwon B, Ko G. Complete genome sequence of *Lactobacillus jensenii* strain SNUV360, a probiotic for treatment of bacterial vaginosis isolated from the vagina of a healthy Korean woman. *Genome Announc* 2017;5:e01757-16. DOI PubMed PMC
74. Bonnardel F, Haslam SM, Dell A, et al. Proteome-wide prediction of bacterial carbohydrate-binding proteins as a tool for understanding commensal and pathogen colonisation of the vaginal microbiome. *NPJ Biofilms Microbiomes* 2021;7:49. DOI PubMed PMC
75. Espino E, Koskenniemi K, Mato-Rodriguez L, et al. Uncovering surface-exposed antigens of *Lactobacillus rhamnosus* by cell shaving proteomics and two-dimensional immunoblotting. *J Proteome Res* 2015;14:1010-24. DOI PubMed
76. Campanero-Rhodes MA, Palma AS, Menéndez M, Solís D. Microarray strategies for exploring bacterial surface glycans and their interactions with glycan-binding proteins. *Front Microbiol* 2019;10:2909. DOI PubMed PMC
77. Halim A, Anonsen JH. Microbial glycoproteomics. *Curr Opin Struct Biol* 2017;44:143-50. DOI PubMed
78. Oliveira de Almeida M, Carvalho R, Figueira Aburjaile F, et al. Characterization of the first vaginal *Lactobacillus crispatus* genomes isolated in Brazil. *PeerJ* 2021;9:e11079. DOI PubMed PMC
79. van der Veer C, Hertzberger RY, Bruisten SM, et al. Comparative genomics of human *Lactobacillus crispatus* isolates reveals genes for glycosylation and glycogen degradation: implications for in vivo dominance of the vaginal microbiota. *Microbiome* 2019;7:49. DOI PubMed PMC
80. Mendes-Soares H, Suzuki H, Hickey RJ, Forney LJ. Comparative functional genomics of *Lactobacillus* spp. reveals possible mechanisms for specialization of vaginal lactobacilli to their environment. *J Bacteriol* 2014;196:1458-70. DOI PubMed PMC
81. Tyagi T, Alarab M, Leong Y, Lye S, Shynlova O. Local oestrogen therapy modulates extracellular matrix and immune response in the vaginal tissue of post-menopausal women with severe pelvic organ prolapse. *J Cell Mol Med* 2019;23:2907-19. DOI PubMed PMC

82. Bradford LL, Ravel J. The vaginal mycobiome: a contemporary perspective on fungi in women's health and diseases. *Virulence* 2017;8:342-51. [DOI](#) [PubMed](#) [PMC](#)
83. Puebla-Barragan S, Watson E, van der Veer C, et al. Interstrain variability of human vaginal *Lactobacillus crispatus* for metabolism of biogenic amines and antimicrobial activity against urogenital pathogens. *Molecules* 2021;26:4538. [DOI](#) [PubMed](#) [PMC](#)
84. Gabriel IM, Vitonis AF, Welch WR, Titus L, Cramer DW. Douching, talc use, and risk for ovarian cancer and conditions related to genital tract inflammation. *Cancer Epidemiol Biomarkers Prev* 2019;28:1835-44. [DOI](#) [PubMed](#) [PMC](#)
85. Dunbar B, Patel M, Fahey J, Wira C. Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors. *Mol Cell Endocrinol* 2012;354:85-93. [DOI](#) [PubMed](#) [PMC](#)
86. Mancini V, Pensabene V. Organs-on-chip models of the female reproductive system. *Bioengineering (Basel)* 2019;6:103. [DOI](#) [PubMed](#) [PMC](#)
87. Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. *Mucosal Immunol* 2017;10:1480-90. [DOI](#) [PubMed](#)
88. Chaichian S, Moazzami B, Sadoughi F, Haddad Kashani H, Zaroudi M, Asemi Z. Functional activities of beta-glucans in the prevention or treatment of cervical cancer. *J Ovarian Res* 2020;13:24. [DOI](#) [PubMed](#) [PMC](#)
89. Ferreira IG, Pucci M, Venturi G, Malagolini N, Chiricolo M, Dall'Olio F. Glycosylation as a main regulator of growth and death factor receptors signaling. *Int J Mol Sci* 2018;19:580. [DOI](#) [PubMed](#) [PMC](#)
90. Zhou JZ, Way SS, Chen K. Immunology of uterine and vaginal mucosae: (trends in immunology 39, 302-314, 2018). *Trends Immunol* 2018;39:355. [DOI](#) [PubMed](#) [PMC](#)
91. Fichorova RN, DeLong AK, Cu-Uvin S, et al. Protozoan-viral-bacterial co-infections alter galectin levels and associated immunity mediators in the female genital tract. *Front Cell Infect Microbiol* 2021;11:649940. [DOI](#) [PubMed](#) [PMC](#)